ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Food Hypersensitivity
Hypersensitivity
Pruritus
Psoriasis

Eczema trials near Philadelphia, PA, USA:

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Enrolling
Eczema Atopic Dermatitis
Eczema, Atopic
Drug: Placebo
Drug: Camoteskimab

Phase 2

Apollo Therapeutics

Philadelphia, Pennsylvania, United States and 35 other locations

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315

Phase 2

Pfizer
Pfizer

Philadelphia, Pennsylvania, United States and 72 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Philadelphia, Pennsylvania, United States and 83 other locations

24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W f...

Active, not recruiting
Atopic Dermatitis
Drug: tralokinumab

Phase 4

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherap...

Enrolling
Atopic Dermatitis
Drug: Dupixent

Phase 4

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients wi...

Enrolling
Atopic Dermatitis
Drug: BxC-I17e
Drug: Placebo

Phase 1

Brexogen

Philadelphia, Pennsylvania, United States and 2 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Philadelphia, Pennsylvania, United States and 537 other locations

The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-seve...

Enrolling
Moderate-to-Severe Atopic Dermatitis
Drug: Nemolizumab

Phase 2

Galderma
Galderma

Philadelphia, Pennsylvania, United States and 22 other locations

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Biological: UCB1381

Phase 1, Phase 2

UCB
UCB

Philadelphia, Pennsylvania, United States and 15 other locations

assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult pa...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Phase 3

AbbVie
AbbVie

Philadelphia, Pennsylvania, United States and 93 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems